Doctor’s orders: Why adherence is critical to improving health outcomes across the life course (ILC, 7 April 2022)

Summary

Nearly half of all adults and approximately 8% of children (aged 5-17) worldwide have a chronic condition. Yet, studies have consistently shown that adherence to medication is poor; estimates range from under 80% to under 50%, with an average of 50%.

There could be a considerable improvement in health outcomes (and consequently longevity), not only by developing new drugs, but by helping people adhere to existing treatment regimens that have already been researched, tested and prescribed for them.

But adherence isn’t usually prioritised by governments, health providers or healthcare professionals (HCPs). Adherence isn’t measured at a national level for any disease, apart from in Sweden where hypertension is recorded. And as governments don’t prioritise adherence, health providers aren’t measured or incentivised for improving it, meaning HCPs may not have the time and resources (or reminders) to focus on it during consultations. 

This report from the International Longevity Centre-UK (ILC) makes a series of recommendations.

Content

Key recommendations

Democratising access

Governments should:

• Fund annual medicine reviews to help people with chronic conditions with decision making and any identified gaps in care, and report on the number of medicine reviews conducted every year across different demographic groups.
• Prevent co-payments from causing a barrier to adherence, as evidence shows they can hinder people from taking prescribed medication.
• Invest in HCP training programmes on behaviour change to supply workers with the requisite skills and knowledge to support adherence to medication regimes and lifestyle behaviour programmes.

Universities should:

• Ensure that undergraduate curricula for all HCPs include an adherence topic that communicates the importance of adherence for the health outcomes of individuals, and helps HCPs to implement effective behaviour change methods.

Inspiring and engaging

Governments should:

• Promote and prioritise adherence as an effective disease management tool, by including it in national chronic disease strategies; for example, those for CVD, osteoporosis and diabetes.
• Set metrics for acceptable adherence rates, and measure and report on adherence rates for chronic conditions, including CVD, diabetes and osteoporosis, at a national (or subnational) level.
• Establish behavioural insight teams with a focus on health, and research the effect of using different incentives to encourage people with chronic conditions to adhere to medications and lifestyle changes.
• Expand the role of pharmacists, with concomitant resources and funding, to allow these professionals to support adherence, monitor for signs of non-adherence and conduct medicine reviews.

WHO should:

• Publish annual adherence rate results, with comparisons between countries.

Providers should:

• Use learnings from the research on the different adherence trajectories for different groups with chronic conditions to develop tailored interventions for people at greater risk of non-adherence.
• Explore using the COM-B model to develop interventions that support individuals to adhere to their medical directions.

Better use of technology

Governments should:

• Invest in research to test how technology, including wearables, can improve adherence.
• Invest in the collection and management of electronic health records, including supporting deidentified assessments of patterns of use and care.
• Ensure that people with chronic conditions can view their health records easily and that records incorporate information and advice to be used as a tool to help with medication adherence and management.

Healthcare providers should:

• Build on the increased use of online consulting during the pandemic to deliver more regular virtual follow-up reviews to check medication adherence and management.